A novel type of organometallic 2-R-2,4-dihydro- 1H-3,1-benzoxazine with R = [M(η5-C5H4)(CO)3] (M = Re or Mn) units. Experimental and computational studies of the effect of substituent R on ring-chain tautomerism by Oyarzo, Juan et al.
A novel type of organometallic 2-R-2,4-dihydro- 1H-3,1-benzoxazine with R = [M(η5-1 
C5H4)(CO)3] (M = Re or Mn) units. Experimental and computational studies of the effect of 2 
substituent R on ring-chain tautomerism† 3 
 4 
 5 
Juan Oyarzo, a Ramón Bosque, b Patricia Toro, a Carlos P. Silva, c Rodrigo Arancibia, d Mercè Font-6 





a Instituto de Química, Pontificia Universidad Católica de Valparaíso, Casilla 4059, Valparaíso, Chile. 12 
b Secció de Química Inorgànica del Departament de Química Inorgànica i Orgànica, Facultat de 13 
Química, Universitat de Barcelona, Martí I Franquès 1-11, E-08028-Barcelona, Spain. 14 
c Departamento de Química de los Materiales, Facultad de Química y Biología, Universidad de Santiago 15 
de Chile, Soft Matter Research-Technology Center, SMAT-C, Av. B. O’Higgins 3363, Casilla 40, 16 
Correo 33, Santiago, Chile 17 
d Laboratorio de Química Inorgánica y Organometálica, Departamento de Química Analítica e 18 
Inorgánica, Facultad de Ciencias Químicas, Universidad de Concepción, Concepción, Chile 19 
e Unitat de Difracció de Raig-X, Centres Científics i Tecnològics (CCiT), Universitat de Barcelona, 20 
Solé i Sabaris, 1-3, E-08028-Barcelona, Spain 21 
f Biomed Division, Health & Biomedicine Unit, LEITAT Technological Center, Parc Científic de 22 




Hugo Klahn: Hugo.klahn@pucv.cl 27 






The syntheses, characterization, X-ray crystal structures, electrochemical properties and anticancer and 34 
antichagasic activities of the first examples of 2-substituted 2,4-dihydro-1H-3,1-benzoxazines with 35 
halfsandwich organometallic arrays, [M(η5-C5H4)(CO)3] (M = Re or Mn), at position-2 are described. 36 
Experimental and computational studies based on DFT calculations on the open forms [Schiff bases of 37 
general formulae R-CHvN-C6H4-2-CH2OH] (5), with R = ferrocenyl (a), phenyl (b), cyrhetrenyl (c) or 38 
cymantrenyl (d), and their tautomeric forms (2-substituted 2,4-dihydro-1H-3,1 benzoxazines) 39 
haveallowed us to establish the influence of substituents a–d and solvents on: (a) the extent of 40 
tautomeric equilibria (5a–5d) ↔ (6a–6d) and (b) their electrochemical properties and the electronic 41 
distribution on the open and closed forms. Despite the formal similarity between 6c and 6d, their 42 
anticancer and antiparasitic activities are markedly different. Compound 6d is inactive in the HCT116, 43 
MDA-MB231 and MCF7 cancer cell lines, but 6c shows moderate activity in the latter cell line, while 44 




Ring-chain tautomerism involving 1,3-N,E (E = S or O) heterocycles has attracted great attention for a 49 
long time.1–4 In this sort of process an iminothiol or an iminoalcohol undergo a reversible 50 
intramolecular C–H addition giving 1,3-N,E heterocycles via a 5- or a 6-endo-trig process (Scheme 1A 51 
and B).1–4 This type of tautomerism is important in synthesis, catalysis and also in physical and 52 
medicinal chemistry.1–7 For E = O, the 6-endo trig process leads to 1,3-oxazines, that are key scaffolds 53 
in drug design,8–11 i.e. 1,3-benzoxazines with potent antibacterial, antifungal and antitumoral activities, 54 
among others, have been described.9,11 On the other hand, bioorganometallic chemistry has undergone 55 
a quick and spectacular growth in the last few decades, leading to organometallic compounds with 56 
relevant, and often new applications.12,13 The incorporation of metallocenes or, to a lesser extent, half-57 
sandwich units into the structure of bioactive molecules or drugs is one of the most promising strategies 58 
in new drug discovery and in Medicinal Organometallic Chemistry (MOC).14 The spectacular 59 
achievements attained with ferrocene-based compounds15–18 [i.e. ferroquine16 (antimalarial agent now 60 
in clinical phase II trials), ferrocifens (potent antitumoral agents)] and other derivatives with remarkable 61 
antibacterial, antifungal, anti-VIH activities, among others15–18 have enhanced interest on complexes 62 
with “[M(η5-C5H4)(CO)3]” units, [M = Re (cyrhetrenyl) or Mn (cymantrenyl)]. Lipophilic and stable 63 
derivatives with interesting electrochemical and photo-physical properties18 and low toxicity are 64 
attractive in MOC. 65 
Cyrhetrene and cymantrene chemistry has undergone a huge development in the last decade.19–22 New 66 
small molecules holding these “[M(η5-C5H4)(CO)3]” (M = Re or Mn) arrays attached to the backbones 67 
of commercially available drugs (i.e. chloroquine, nifurtimox, daunorubicin)19c and biomolecules (i.e. 68 
nucleobases and19a,b peptides22d–f ) or with scaffolds of biological relevance (i.e. sulfones20b and 69 
heterocycles20f) are becoming more and more popular.19–21 Compounds of this kind with outstanding 70 
biological activities have been reported.19–21 The chloroquine conjugates I and II (Fig. 1) have a potent 71 
inhibitory growth effect in Trypanosoma brucei [IC50 = 3.5 μM (for I) and 0.6 μM (for II)].20d 72 
Sulphonamides III with better antitubercular activity than their ferrocenyl analogues are known.20b The 73 
cyrhetrenyl derivative IV has higher inhibitory growth potency on Trypanosoma cruzi epimastigotes 74 
(Dm28c strains) (IC50 = 2.4 μM) than those of compound V (IC50 = 12.3 μM) and nifurtimox (IC50 = 75 
19.8 μM).20b Imines VI and VII are capable of inhibiting the growth of MCF7, MB-MDA231, and 76 
HCT116 cancer cell lines. Compound VII, (more active than VI), is two times more potent than cis-77 
[PtCl2(NH3)2] (cisplatin) in MDA-MB231 and HCT116 colon cell lines.20i In fact, nowadays 78 
cyrhetrenyl and cymantrenyl derivatives are among the most promising candidates to achieve new drugs, 79 
more efficient and less toxic than those currently used to treat diseases causing high mortality (i.e. 80 
Chagas, malaria and cancer). Despite of this, and increasing interest on: (a) tautomeric equilibria shown 81 
in Scheme 1, (b) 1,3-benzoxazine derivatives, that may form via a 6-endo trig process and, (c) ferrocene, 82 
cyrhetrene and cymantrene derivatives with bioactive arrays in MOC, compounds of this kind showing 83 
this sort of ring-chain tautomerism are scarce.5–7 Only three articles have been reported so far.5–7 Two 84 
involve a five-endo trig process that transforms imines (1 or 3 in Fig. 2) into their closed forms (2 and 85 
4),5,6 while the third is the 6-endo trig process (shown in Fig. 2), involving 5a and 2-ferrocenyl-2,4-86 
dihydro-1H-3,1-benzoxazine (6a).7 As far as we know, parallel studies on cyrhetrene or cymantrene 87 
derivatives have not been undertaken so far. 88 
In this work, we present the first two examples of 2,4-dihydro-1H-3,1-benzoxazines with the [M(η5-89 
C5H4)(CO)3] {M = Re or Mn} units on position 2; together with experimental and theoretical studies 90 
aimed to clarify the effect of the four substituents {ferrocenyl (a), phenyl (b), cyrhetrenyl (c) and 91 
cymantrenyl (d)} and the solvents on the stability of the imines [R{–CHvN-(C6H4-2-CH2OH)}] (5a–d), 92 
their closed tautomers (6a–d) and the tautomeric equilibria 5(a–d) ↔ 6(a–d). 93 
94 
Results and discussion  95 
Synthesis 96 
The treatment of equimolar amounts of cyrhetrenylcarboxaldehyde [Re(η5-C5H4-CHO)(CO)3]23 and 97 
2-aminobenzylalcohol in benzene under reflux for 12 h using a Dean–Stark apparatus to remove the 98 
benzene–water azeotrope formed in the course of the reaction produced a colorless solution. Further 99 
concentration to dryness followed by successive washings of the residue with n-hexane gave a pale 100 
yellowish solid (herein after referred to as 6c). Its high resolution mass spectrum (Fig. S1†) showed a 101 
peak at m/z = 470.0394 that is consistent with that of the cation {[M] + H}+ (m/z = 470.0402) formed 102 
from any of the two tautomers [the imine (5c) or its closed form (6c)]. The IR spectrum of 6c (Fig. S2†) 103 
showed typical bands due to the CO ligands of the cyrhetrenyl unit (in the range 1900–2100 cm−1)20l 104 
and an intense and sharp absorption at 3325 cm−1, due to the stretching of the N–H bond, that is 105 
characteristic of 2,4-dihydro-1H-3,1-benzoxazines.6,8,11 These findings suggested that the isolated 106 
solid was 2-cyrhetrenyl-2,4-dihydro-1H-3,1-benzoxazine (6c in Scheme 2) and the X-ray diffraction 107 
studies (described below) confirmed it. 108 
In contrast to these results, when the reaction was carried out under identical experimental conditions, 109 
but using [Mn(η5-C5H4-CHO)(CO)3],24 the 1H-NMR spectrum of the raw material isolated after 110 
concentration and successive washing with n-hexane at room temperature (Fig. S3†) revealed the 111 
coexistence of at least four species in solution, two of them being the starting reagents. The singlet 112 
observed at δ = 8.01 suggested the presence of the imine form (5d). The set of resonances assigned to 113 
the major component were consistent with those expected for 2-cymanthrenyl-2,4-dihydro-1H-3,1-114 
benzoxazine (6d) depicted in Scheme 2. Since this reaction was performed under identical conditions 115 
used for the ferrocenyl, phenyl and cyrhetrenyl aldehydes, the results obtained from the NMR studies 116 
suggest that [Mn(η5-C5H4-CHO)(CO)3] is less prone to react with the aminoalcohol compared to its 117 
Re(I) analogue, or even to the ferrocenyl- or phenyl-aldehydes. Despite these findings, the complete 118 
reaction of the aldehyde [Mn(η5-C5H4-CHO)(CO)3] with the aminoalcohol was successfully achieved 119 
using an excess (20%) of the aldehyde and longer refluxing periods (24 h). Further purification of the  120 
crude material by SiO2 column chromatography gave a pale brownish solid. Mass spectra showed a 121 
peak (Fig. S4†) at m/z =338.0220, which agrees with those expected for the {[M] + H}+ cations (m/z = 122 
338.0225) of both tautomers. The IR spectrum of 6d also showed the band due to the stretching of the 123 
N–H bond (at 3322 cm−1), quite close to that detected in the spectrum of its Re(I) analogue, 6c (at 3325 124 
cm−1) and slightly shifted in relation to that of the ferrocenyl analogue (6b) (at 3348 cm−1). These 125 
results suggest that the isolated solid was the closed form 6d (Fig. S5†), and X-ray diffraction studies 126 
(see below) confirmed this finding. 127 
For comparison purposes (see below) we also studied the reactions between the aldehydes [M(η5-C5H4-128 
CHO)(CO)3] (M = Re or Mn) and 2-aminophenol under identical experimental conditions to 6c (see the 129 
Experimental section). In the two cases, the isolated products were identified as the imines [M{(η5-130 
C5H4)-CHvN-(C6H4-2-OH)}(CO)3] (with M = Re (7c) or Mn(7d)). 131 
 132 
Characterization of the compounds 133 
Compounds 6c and 6d were isolated as greenish (6c) or brownish (for 6d) crystals and show high 134 
stability in the solid state at room temperature. They are soluble in common solvents (i.e. CH3CN, 135 
CH2Cl2, CHCl3, ethyl acetate, benzene, dimethyl sulfoxide,and even mixtures of DMSO : H2O). These 136 
products were characterized in the solid state and also in solution. In the two cases elemental analyses 137 
(see the Experimental section) were consistent with the calculated values for their proposed formulae.  138 
Their HRMS (Fig. S1 and S4A†) showed a peak at m/z = 470.0394 (for 6c) and at 338.0220 (for 6d), 139 
that agree with those expected for the corresponding {[M] + H}+ cation and their EI-mass spectra [Fig. 140 
S1B (for 6c) and S4B† (for 6d)] showed the peaks due to the cations [M]+; [M − CO]+; [M − 2CO]+ 141 
and [M − 3CO]+. The melting points of 6c and 6d are higher than those of their ferrocenyl- and phenyl-142 
analogues (6a and 6b, respectively) and follow the trend: 6a (96 °C) < 6b (119 °C) < 6d (120 °C) < 6c 143 
(148 °C). 144 
 145 
Description of the crystal structures 146 
Compounds 6c and 6d were also characterized by X-ray diffraction and for comparison purposes we 147 
also crystallized and solved the crystal structure of the ferrocenyl derivative (6a) whose synthesis was 148 
reported previously6 (Table S1†). It should be noted that: (a) two different molecules (hereinafter 149 
referred to as A and B) were found in the crystals of 6c and, (b) in 6a the atoms of the C5H5 ring of the 150 
ferrocenyl unit were found in disordered positions. In all cases, the crystal structures confirmed the 151 
existence of the 2,4-dihydro-1H-3,1-benzoxazine array with a ferrocenyl (in 6a, Fig. 3), a cyrhetrenyl (in 152 
6c, Fig. 4) or a cymantrenyl (in 6d, Fig. 5) group attached to position 2. Bond lengths and angles of the 153 
1,3-N,O heterocycle in compounds 6a, 6c and 6d (Table 1) are very similar (the differences do not 154 
clearly exceed 3σ), and agree with the values found in related 2-phenyl substituted derivatives described 155 
previously.25,26 The non-planar oxazine rings27 exhibit a distorted half-chair conformation in 6a and a 156 
slightly distorted envelope-type in 6c (molecules A and B) and in 6d.28  157 
In all cases, the heteroatoms O1 and N1 are located on opposite sides of the plane defined by the C5H4 158 
ring. The O1 atom deviates from this plane by ca. 0.30 Å (in 6a); 0.42 Å and 0.63 Å (in molecules A and 159 
B of 6c) and 0.70 Å (in 6d) towards the metal centre. However, the separations O1⋯M 3.709 Å (in 6a), 160 
3.732 Å and 3.750 Å (in molecules A and B, respectively of 6c) and 3.724 Å (in 6d) are greater than the 161 
sum of their van der Waals radii.29 162 
The substituted pentagonal rings of the organometallic array are planar and twisted in relation to the 163 
phenyl ring of the bicyclic system, angles between their main planes being 55.05° (in 6a); 68.47° and 164 
34.7° (in molecules A and B of 6c) and 68.07° in 6d. Bond lengths and angles of the (η5-C5H5)Fe (η5-165 
C5H4) unit of 6a agree with those reported for most monosubstituted ferrocene derivatives.25 166 
The assembly of the molecules in the crystals is complex due to the existence of a wide variety of 167 
intermolecular interactions. In the three cases, the hydrogen atom of the >NH unit plays a key role in the 168 
assembly of the molecules. In 6a and 6d the relative orientation of this H atom and the phenyl ring of a 169 
vicinal molecule allows their assembly by N–H⋯π interactions. In 6c, proximal molecules of the same 170 
type (A or B) are also connected due to these intermolecular short contacts. 171 
The relative arrangement of the units in the crystals of 6a, 6c and 6d also allows C–H⋯π interactions, 172 
for instance between one of the H atoms of the –CH2– unit [H13B] and the unsubstituted ring of the 173 
ferrocenyl unit of a proximal molecule in 6a. For the cymantrenyl derivative (6d), the separation 174 
between the C6–H6 bond and the centroid of the ring defined by a set of atoms C(7)–C(12) is 2.85 Å. 175 
This suggests the existence of C–H⋯π intermolecular contacts. In 6c, these contacts involve the C6–H6 176 
bond of molecule A at (x, y, z) and the phenyl ring of a B type unit located at (1 − x, 1 − y, −1/2 − z) and 177 
vice versa, assembling molecules A and B in the crystals.Moreover, in the cyrhetrenyl and cymantrenyl 178 
derivatives, additional CO⋯H intermolecular contacts30 between one oxygen of the CO ligands [O2 (in 179 
6c) and O3B in 6c (molecule B)] or two [O3B and O4B (in type B molecules)] and one hydrogen atom 180 
of the C5H5 ring of a proximal molecule31 extend the assembly of the molecules in the crystals of 6c 181 
and 6d. 182 
 183 
Characterization in solution 184 
NMR studies have been a useful tool not only to characterize the new compounds in solution, but also: 185 
(a) to test their stability in solution, especially in the solvents used for the electrochemical and biological 186 
studies described below, (b) to evaluate the effect of the solvent on the ring-chain tautomerism of the 187 
new products and (c) to establish the influence of the nature of the four substituents R2 on the 188 
tautomeric equilibrium between imines 5a–5d and their closed forms (6a–6d). For all these studies the 189 
identification of the protons follows the pattern presented in Fig. S6.† 190 
Proton-NMR spectra of freshly prepared solutions of 6c and 6d in acetonitrile-d3 (Fig. S7 and S8†) 191 
showed a set of two doublets and two triplets assigned to the aromatic protons (H3–H6) and a group of 192 
four complex multiplets due to the protons of the C5H4 ring. The remaining resonances observed in the 193 
spectra (doublet, a doublet of doublets and a broad signal) are characteristic of the protons of the >CH–, 194 
the –OCH2 and the NH units of the six-membered 1,3-N,O heterocycle, thus indicating that the closed 195 
forms (6c or 6d, respectively) were present in this solvent at room temperature. A careful analysis of the 196 
1H-NMR spectra of 6c and 6d revealed the existence of another set of resonances with low intensity 197 
(Fig. S7 and S8,† respectively) indicating the presence of a minor component in acetonitrile-d3 at 298 198 
K. The presence of a singlet in the range 8.00 < δ < 8.20 ppm suggested the presence of the imine forms 199 
5c and 5d. Integration of the well-separated doublet due to one of the protons of the –OCH2– moiety of 200 
6c (or 6d) of the imine protons of 5c (at δ = 8.16 ppm) (or 5d at δ = 8.14 ppm) (Fig. S7 and S8†) 201 
allowed us to determine the relative abundance of the tautomers in acetonitrile-d3 (molar ratios 6c : 5c ≈ 202 
1.00 : 0.02 and 6d : 5d ≈ 1.00 : 0.04) (we will return to this point later on). 203 
In order to fulfil the characterization of the new compounds in this solvent we also registered their 204 
13C{1H}-NMR spectra (Fig. S9 and S10†). The assignment of the resonances observed in the 1H and 205 
13C{1H}-NMR spectra was achieved with the aid of two-dimensional NMR experiments {ESI: [1H–206 
1H]-NOESY (Fig. S11 and S12), [1H–13C]-HSQC (Fig. S13 and S14) and [1H–13C]-HMBC (Fig. S15 207 
and S16)†}. In the [1H–1H]-NOESY spectra the cross-peaks between the signals due to protons of the –208 
CH2– unit and one of the doublets observed in the aromatic region allowed the assignment of the signal 209 
due to the H3′ proton. Besides that, the identification of the signals due to the protons (H2 and H5) on 210 
the ortho sites of the (η5-C5H4) ring and to the H6′ was carried out on the basis of the NOE peaks 211 
involving these protons and those of the >CH–NH– unit. 212 
These NMR studies revealed that the closed forms (6c and 6d) were the major components present in 213 
acetonitrile-d3 solutions at 298 K and coexisted with small amounts (<3.0%) of their corresponding 214 
imine forms: [R{–CHv(N-C6H4-2-CH2OH)}] (5c and 5d, respectively). Therefore, under these 215 
experimental conditions the tautomeric equilibrium is strongly shifted towards the 2-cyrhetrenyl (6c) or 216 
the 2-cymantrenyl (6d) -2,4-dihydro-1H-3,1-benzoxazine derivatives. 217 
 218 
Electrochemical studies 219 
As mentioned above, 1,3-benzoxazines and their derivatives have a wide range of applications, in which 220 
their electrochemical properties are a keystone, for instance their use or transformation to achieve resins 221 
or polymers.8,32 Moreover, it is well-known that their proclivity to undergo an oxidation process in 222 
biological media is also relevant in view of their utility in new drug design and development.8,11,33 In 223 
view of these findings, we also studied the electrochemical properties of the new compounds (6c and 6d) 224 
and compared them with those of the ferrocenyl- (6a) and phenyl- (6b) analogues (previously reported) 225 
under identical experimental conditions. The comparison of the results obtained for products 6a–6d may  226 
allow the elucidation of the effect of the four substituents (a–d) on position 2 on their electrochemical 227 
properties. 228 
In all cases the electrochemical studies were carried out by cyclic voltammetry. The solvent selected for 229 
these studies was acetonitrile because of the fact that (a) NMR studies in acetonitrile-d3 confirmed the 230 
stability of the products in this solvent, and, (b) it is well-known that the nature of the products formed 231 
by the oxidation of 1,3-benzoxazines is strongly dependent on the solvent and additives.8,32 Oxidation 232 
in acetonitrile produces preferentially radicals, which may have a key role in the biological medium [e.g. 233 
formation of reactive oxygen species (ROS)] and the metabolic degradation of 1,3-benzoxazines.8,33 234 
Cyclic voltammetries of freshly prepared (10−3 M) solutions of the corresponding compounds (6a–6d) 235 
in acetonitrile (HPLC-grade) with (Bu4N)[PF6] as the supporting electrolyte were carried out at 298 K 236 
and a scan rate υ = 250 mV s−1. The cyclic voltammograms (hereinafter referred to as CV) are shown in 237 
Fig. 6 and a summary of the electrochemical data is presented in Table 2.  238 
The CV of 6a shows the typical anodic peak (I) and its corresponding reduction one in the reverse scan 239 
(I′) between −1.2 V and 0.6 V. These peaks [with EI pa = 0.107 V and EI′ pc = 0.032 V], not observed 240 
in the CV of 6a–6d, are due to the electrochemical one electron oxidation–reduction of the ferrocenyl 241 
unit. 242 
In all cases the voltammograms showed above 0.5 V another anodic peak (hereinafter referred to as II), 243 
which according to the bibliography could be attributed to the oxidation of the benzoxazine unit.8,32 244 
The position of this peak is strongly dependent on the nature of the substituent and moves to the anodic 245 
region according to the sequence 6b < 6d < 6c ≪ 6a. This reflects a decrease of proclivity of the benzox-246 
azine array to undergo the oxidation process. It should be noted that for 6a, this electrochemical process 247 
takes place after the oxidation of the ferrocenyl unit. This may explain the strong shift (to higher 248 
potentials) of peak II of 6a in comparison to those of 6b, 6c and 6d. At higher potentials the cyclic 249 
voltammograms of compounds 6b–6d show a broad and poorly defined peak (III). 250 
For 6c and 6d, the additional oxidation peaks at around 1.2 V (labelled as IV in Fig. 6) are assigned 251 
(according to the bibliography) to further oxidation processes involving Re(I) (in 6c) or Mn(I) in 252 
6d.8,19b,20e–i,22i,34,35 For the Re(I) complex the position of this peak appears at lower potentials than 253 
for imine [Re(η5-C5H4-CHvN-R2)(CO)3] VII as shown in Fig. 1 [with Epa = 1.420 V (under identical 254 
experimental conditions)].20h This suggests that the replacement of the ferrocenyl unit of VII by the 255 
2,4-dihydro-1H-3,1-benzoxazine scaffold to give 6c enhances the proclivity of Re(I) to undergo 256 
oxidation.20i For 6d, the peak due to the oxidation of Mn(I) appears at higher potentials than for 257 
[Mn(η5-C5H5)(CO)3] (E = 0.92 V),34 but within the range (1.00 V–1.37 V) reported for cymantrene 258 




Study of the stability of the compounds 6c–6d and 7c–7d in solution and the effect of the solvent 263 
on the tautomeric equilibrium 264 
It is well-known that for 2-aryl substituted benzoxazines, the ratio between the closed form and its open 265 
chain tautomer depends on several factors, of which the electronic nature of the substituent and the 266 
properties of the solvent are probably those with greater relevance. 267 
To elucidate whether the tautomeric equilibria could be tuned by the solvent, further 1H-NMR studies 268 
were undertaken at 298 K in several deuterated solvents (CD2Cl2, C6D6 and DMSO-d6) with different 269 
polarities and dielectric constants.36 In all cases, the compounds were dissolved in the deuterated 270 
solvent and the solution was allowed to stand for some time to be sure that the equilibrium was reached. 271 
The relative abundance of the closed (6) and open (5) forms in each case was determined as described 272 
above (see Characterization in solution). 273 
1H-NMR spectra of the solutions of compounds 6c and 6d in CD2Cl2 (Fig. S17 and S18†) also revealed 274 
that the closed forms were the major components present in solution and coexisted with tiny amounts of 275 
the imine forms in molar ratios quite similar to those obtained in acetonitrile-d3. Moreover, these studies 276 
revealed that new compounds (6c and 6d) are clearly more stable in CD2Cl2 than their analogues with 277 
ferrocenyl- of phenyl-derivatives for which 1H-NMR studies revealed the presence of greater amounts 278 
of the open forms (5a and 5b) (Fig. S19 and S20†), even after short periods of storage at 298 K, than for 279 
their cyrhetrenyl and cymantrenyl analogues. Moreover, as the storage period increased, the typical 280 
singlets due to ferrocenecarboxaldehyde (for 6a) {or to a minor extent also benzaldehyde (for 6b)} were 281 
also detected by NMR, thus indicating the low stability of the aldimines 5a and 5b in this solven 282 
In contrast to the results obtained in acetonitrile-d3 and CD2Cl2, in benzene-d6, (Fig. S21 and S22†) no 283 
evidence of the presence of the imine forms was observed in any of the two cases, thus suggesting that 284 
the equilibrium is strongly displaced towards the closed forms (6c and 6d). This is markedly different to 285 
that observed for their ferrocenyl analogue, for which the closed (6a) and open (5a) forms co-existed in a 286 
molar ratio: 6a/5a = 1.1. Therefore the replacement of the ferrocenyl unit by the [M(η5-C5H4)(CO)3] 287 
arrays favours the displacement of the tautomeric equilibria towards the closed forms.  288 
Finally, it should be noted that additional NMR studies of the solutions of compounds 6c and 6d in 289 
DMSO-d6 did not reveal the presence of the imine forms. Moreover, no significant difference was 290 
observed in the spectra of the freshly prepared solutions and those recorded after different periods of 291 
storage at 298 K (Fig. S25 and S26†). This indicates that both compounds also exhibit high stability in 292 
DMSO-solutions. 293 
NMR spectra of compounds 7c and 7d, in CDCl3 (Fig. S27 and S28†), showed a set of signals, whose 294 
intensities and chemical shifts were consistent with those expected for the imines [M{(η5-C5H4)-295 
CHvN-(C6H4-2-OH)}(CO)3] with M = Re (7c) or Mn (7d). For these products no evidence of the 296 
presence of any other species in solution could be detected by 1H-NMR. These findings indicate that 297 
imines 7c and 7d are not prone to undergo the formation of the 1,3 N,O heterocycle through a 5-endo 298 
trig process. In contrast to the results obtained for 6c and 6d, 1H-NMR spectra of freshly prepared 299 
solutions of 7c and 7d at 298 K changed with time (Fig. S29 and S30†). After 4 h of storage, the 300 
spectrum of 7c showed an additional singlet at δ ≈ 9.6 ppm, which is indicative of the presence of free 301 
cyrhetrenylcarboxaldehyde. For the Mn analogue (7d), the spectrum obtained after 4 h was more 302 
complex and showed additional sets of signals with low intensity that suggested the presence of several 303 
species in solution. As shown in Fig. S30† after 24 h of storage the spectrum showed low resolution due 304 
to the broadening of the signals. The comparison of the results obtained for 7c and 7d reveals that both 305 
decompose gradually in DMSO-d6 at 298 K. For the Mn(I) derivative (7d) the process is faster and 306 
more complex than for its Re(I) analogue 7c. These findings are markedly different from those observed 307 
for their benzoxazine analogues 6c and 6d, for which their 1H-NMR spectra in DMSO-d6 did not show 308 
any significant change after long periods of storage at the same temperature. 309 
 310 
Theoretical studies 311 
In a first attempt to rationalize the influence of the organometallic array on ring-chain tautomerism, we 312 
decided to undertake DFT calculations for the open forms (5a–5d) and their corresponding tautomers 313 
(6a–6d). Theoretical calculations were performed at the B3LYP hybrid functional37 using the 314 
LANDL2DZ (for Re and Mn)38 and the 6-31G*39 (for the remaining atoms) basis set implemented in 315 
the Gaussian 03 software.40 The geometries of the open forms [R{–CHvN-(C6H4-2-CH2OH)}] (5a–316 
5d) and their closed tautomers (6a–6d) were optimized. Final atomic coordinates for the optimized 317 
geometries are presented in Tables S2–S9.† 318 
Optimized geometries of the open forms (5a–5d) revealed the existence of an intramolecular interaction 319 
between the imine nitrogen and the pendant –OH arm (Table S10†). It is well-known that for 2-320 
phenyloxazolidines the influence of the substituents on the aryl ring on position 2 on the stability of the 321 
tautomers is controlled by several factors of which the intramolecular O–H⋯N bond appears to be 322 
especially relevant. The formation of the heterocycle requires the cleavage of the O–H⋯N bond and 323 
proper orientation between the oxygen on the –OH group and the imine carbon. Consequently, imines 324 
with weaker O–H⋯N bonds and closer O and Cimine atoms are expected to be more prone to undergo 325 
the 6-endo trig process. 326 
In imines 5a–5d, the –OH bond lengths are quite similar [in the range 0.973 Å (for 5b) and –0.977 Å 327 
(for 5a)]. For compounds 5a, 5c and 5d with the (η5-C5H4) attached to the imine carbon, the N⋯H 328 
distance increases as follows: 1.959 Å (for 5a) ≪ 2.023 Å (for 5c) < 2.027 Å (for 5d). This suggests that 329 
in the ferrocenyl derivative (5a) the N⋯H interaction is stronger than in the cyrhetrenyl (5c) and 330 
cymantrenyl (5d) analogues and therefore less prone to undergo the formation of the closed form. This 331 
agrees with the results obtained from the NMR studies described above, which proved the co-existence 332 
of the closed (6) and open (5) forms in acetonitrile-d3 or CD2Cl2 solutions at 298 K in different molar 333 
ratios that increased according to the sequence: 6a/5a ≪ 6c/5c < 6d/5d. 334 
In order to gain further insight into this tautomeric process and after the optimization of the geometries 335 
of the open (5a–5d) and closed forms (6a–6d), we compared the electronic energy (ET) of the imines 336 
(5a–d) and their tautomers (6a–6d) in a vacuum as well as in CH2Cl2 solutions and in both cases, the 337 
ET values obtained for the closed forms were clearly lower than those of their corresponding imine 338 
forms (Table S11†). 339 
The solution studies described above showed that in CD2Cl2 the molar ratios 6d/5d and 6c/5c were 340 
greater than those observed for the set of compounds holding a phenyl (b) or a ferrocenyl (a) unit, 341 
indicating that the presence of the cyrhetrenyl or cymantrenyl units shifts the tautomeric equilibrium 342 
towards the closed forms. In view of this, additional computational studies were carried out in order to 343 
determine the free energy of the open (5a–d) and closed (6a–d) forms in CH2Cl2 at 298 K. The 344 
comparison of the results [Table S11,† A] reveals that the imine forms are less stable compared to their 345 
tautomers with identical substituents. Moreover, for the three organometallic pairs of compounds with a 346 
(η5-C5H4) ring attached to the imine carbon in the open forms (5) or to position 2 of the benzoxazines 347 
in the closed tautomers (6), the comparison of the values of the free energy for the process 6i → 5i [ΔGi, 348 
defined as: ΔG(for 5i)–ΔG(for 6i)] (with identical substituent i = a, c or d) [see Table S11,† B] increases 349 
according to the sequence a < c < d. This trend suggests that compounds 6c and 6d with [M(η5-350 
C5H4)(CO)3] (M = Re or Mn) units are less prone to undergo a ring opening process compared to their 351 
ferrocenyl analogue 6a. This could explain the greater abundance of the closed forms 6c or 6d detected 352 
in CD2Cl2 solutions at 298 K solution, when compared to that of 6a. Moreover, it is well known that the 353 
stability of ferrocenylimines in solution is strongly dependent on the solvent used and its quality. Traces 354 
of water or acids present in CD2Cl2 or CDCl3 solutions frequently promote their hydrolysis.39,20i,41 355 
Compounds of general formulae [(η5-C5H5)Fe{(η5-C5H4)-CHvN-R}] with phenyl groups attached to 356 
the imine nitrogen are less prone to hydrolysis compared to their analogues with alkylic substituents, 357 
and a similar phenomenon has also been described for the hybrid ferrocenyl/cyrhetrenyl derivative [(η5-358 
C5H5)Fe{(η5-C5H4)-CHvN-(η5-C5H4)Re(CO)3}] (VI, in Fig. 1).20i Degradation of the aldimine 5a is 359 
expected to shift the equilibrium 6a ↔ 5a towards the right and this explains the coexistence of 6a, 5a 360 
and [Fe(η5-C5H5){(η5-C5H4)-CHO}], (formed by the hydrolyses of 5a) after several hours of storage 361 
of a solution of 6a in CD2Cl2 at 298 K (Fig. S19†). 362 
The comparison of the frontier orbitals of the closed forms 6a–6d can be useful to clarify the effect of 363 
the substituents on the electronic distribution of molecular orbitals; we also undertook molecular orbital 364 
calculations for the closed forms 6a–6d. Frontier orbitals [HOMO−1, HOMO, LUMO and LUMO+1] 365 
are depicted in Fig. 7. For compounds 6a, 6c and 6d, HOMO−1 is mainly centred on the corresponding 366 
organometallic fragments; while in their phenyl analogue in 6b, it is basically located on the phenyl ring 367 
of the bicyclic system with a tiny contribution of the –OCH2– unit and the remaining C6H5 ring. Except 368 
for compound 6a, in which the atomic orbitals of the Fe(II) ion have a significant contribution on the 369 
HOMO orbital, for 6b–6d it is mainly centred on the aromatic ring of the benzoxazine array and the 370 
heterocyclic nitrogen, without any significant participation of the organometallic “[M(η5-C5H4)(CO)3]” 371 
units of 6c and 6d. However, the replacement of the phenyl ring of 6b by the cyrhetrenyl- or 372 
cymantrenyl-arrays (in 6c and 6d), respectively, is important to modify the relative contribution of the 373 
atomic orbitals in their HOMO and especially that of the nitrogen. Therefore, the oxidation of 374 
compounds 6b–6d requires the removal of one electron on the HOMO orbital centred on the bicyclic 375 
system. The energy of their HOMO orbitals increases according to the sequence: 6b < 6c < 6d. (Table 376 
S12†), but it should be noted that these calculations were performed under vacuum and therefore no 377 
solvent effects were included in this calculation. This may explain the differences observed between the 378 
trend of their E(HOMO) and the experimental EII pa values (obtained from cyclic voltammetries in 379 
acetonitrile). 380 
As shown in Fig. 7 the LUMO is basically a π* orbital of the ferrocenyl (in 6a), the [M(η5-C5H4)] units 381 
of 6c or 6d or the two phenyl rings of 6b. The LUMO+1 orbital is located on the organometallic units of 382 
compounds 6a, 6c and 6d, while in 6b it is a combination of π* orbitals of the two phenyl rings.  383 
We also compared the energies of the HOMO and LUMO orbitals and the values of their energy gaps 384 
(Egap) for compounds 6a–6d. As shown in Table S12,† the values of Egap increase according to the 385 
sequence 6d < 6c < 6a < 6b. This should affect the position of the band detected in the absorption 386 
spectra due to the transition HOMO → LUMO. ESI contains the UV-vis spectra of the complexes in 387 
CH2Cl2 at 298 K (Fig. S31) and a summary of UV-vis data is presented in Table S13.† 388 
Due to increasing interest of fused rings containing heteroatoms with good donor abilities as ligands for 389 
transition metals, a comparative analysis of the charge distribution on the heterocycle was also carried 390 
out. The results presented in Table S12† reveal that the nature of the substituent produces significant 391 
variations in the calculated charges of the carbon and oxygen atoms of the “CH2–O–CH” unit. For 392 
compounds 6a, 6b and 6c the charge on the nitrogen is very similar, but all of them are smaller than that 393 
obtained for their Mn(I) analogue (6d). This difference may be important in view of its reactivity and 394 
potential capability to be used as a ligand in front of transition metals.  395 
 396 
Biological studies 397 
As mentioned above organometallic compounds with fac-[M (η5-C5H5)(CO)3] cores and 3,1-398 
benzoxazine derivatives are attractive in view of their utility in new drug design. The new compounds 399 
6c and 6d presented in this work contain both units simultaneously and coexist in solution with small 400 
amounts of their open forms 5c and 5d. Moreover, it is wellknown that Schiff bases may also exhibit 401 
interesting biological activities. For instance, compound VI presented in Fig. 1 and other aldimines of 402 
general formulae: [(η5-C5H5)Fe{(η5-C5H4)-CHvN-R}] with potent anticancer activities have been 403 
reported. 20i,42 In view of these, we also decided to perform additional studies in order to evaluate their 404 
biological activities as anticancer or as anti-parasitic agents 405 
1H-NMR studies (described above) of the ferrocenyl- or the phenyl-derivatives (6a and 6b, respectively) 406 
and also the new imines [M{(η5-C5H4)-CHvN-(C6H4-2-OH)}(CO)3] {M = Re (7c) or Mn (7d)} 407 
demonstrate that: (a) 6a and 6b exhibit low stability in solution due to the hydrolyses of their open form 408 
tautomers (5a and 5b); (b) compound 7c decomposes in DMSO-d6 at 298 K and the degradation of its 409 
Mn analogue (7d) is even faster and more complex than that of 7c under identical experimental 410 
conditions. Unfortunately, these findings reduce significantly their potential for new drug design, and 411 
this is the main reason why compounds 6a, 6b, 7c and 7d were not included in the biological studies 412 
described in this section.  413 
In a first stage, in vitro studies on the effect produced by the new compounds 6c and 6d on the same set 414 
of cancer cell lines used before for imines VI and VII (shown in Fig. 1) were performed. The effects of 415 
6c and 6d on HCT-116 (colon), the MDA-MB231 and the MCF7 breast cancer cell lines and of 416 
cisplatin, used as the positive control, were assessed after 72 h and the results are presented in Table 3 417 
and Fig. 8.  418 
In the HCT-116 cell line the Mn(I) derivative (6d) resulted to be less potent compared to its Re(I) 419 
analogue (6c), but their inhibitory growth potency was clearly smaller than that of cisplatin. For the 420 
triple negative (ER, PR and no HER overexpression) MDA-MB231 breast cancer cell line, the results 421 
(Fig. 8 and Table 3) were even worse than in HCT-116. Neither 6c nor 6d showed any relevant activity 422 
(IC50 > 100 μM). However, parallel studies on MCF-7 revealed that the Re(I) compound (6c) has a 423 
greater antiproliferative effect than its Mn(I) analogue (6d), but its potency is clearly smaller than those 424 
of the reference drug and imine VII (IC50 = 12 ± 5.2 μM).20i  425 
We also undertook a comparative study of the effect of the new products (6c and 6d) on the normal and 426 
non-tumoral human skin fibroblast BJ cell line. The results obtained (Fig. 9) reveal that the Re(I) 427 
derivative (6c) [IC50 = 65.3 ± 2 μM] is a bit less toxic compared to its Mn(I) analogue 6d [IC50 = 52.6± 428 
2 μM] and both exhibit a lower inhibitory growth effect than cisplatin (IC50 = 21 ± 2 μM) under 429 
identical experimental conditions. This finding together with the high stability of the new compounds is 430 
particularly attractive for further studies centred on their biological activities in other areas. 431 
In view of the results obtained from the in vitro cytotoxic activity of the compounds in the cancer cell 432 
lines, and especially in the normal and non-tumoral BJ cells we focused our attention on their evaluation 433 
as potential antiparasitic agents. With this aim in mind, the Trypanosoma cruzi epimastigotes (Dm28c 434 
strain) were incubated with various concentrations of compounds 6c and 6d and for comparison 435 
purposes a parallel study with nifurtimox (one of the drugs used currently in the treatment of Chagas 436 
diseases) was also undertaken under identical experimental conditions. As shown in Fig. 10 despite the 437 
formal similarity between 6c and 6d, their inhibitory growth effect on the selected strain of parasites was 438 
markedly different. The Re(I) complex (6c), the more potent anticancer agent than 6d on HCT-116 and 439 
MCF7, showed no significant anti-Trypanosoma cruzi activity (Fig. 10). In contrast to these results 6c 440 
exhibited antiparasitic activity with an inhibitory growth potency greater than that of the aldimine 441 
[Re{(η5-C5H4)-(CH2)-NvCHR}(CO)3] with R = 5-nitrofurane (IC50 = 87.7 ± 2.1 μM) and practically 442 
identical to that of the 4-nitrothiophene analogue (IC50 = 43.1 ± 0.8 μM), but clearly below that of 443 
nifurtimox (IC50 = 17.4 ± 0.3 μM under identical conditions) and the Re(I) complex IV presented in 444 
Fig. 1 (IC50 = 2.4 μM).20b 445 
Since compounds 6c and 6d have an identical set of organic ligands and a 2,4-dihydro 3,1-benzoxazine 446 
unit connected to the [M(η5-C5H4)(CO)3] units, they differ exclusively in the nature of the M(I) atom 447 
[M = Re(I) (in 6c) or Mn(I) (in 6d)]. The results obtained from these biological studies reveal that the 448 
replacement of Re(I) of 6c by Mn(I) to give 6d is important as to induce significant variations in their 449 
antichagasic activity. This finding is in sharp contrast to the previous results summarized in a recent 450 
review as follows: “if the metaltricarbonyl core is covalently bound to an organic molecule the obtained 451 
antiparasitic activity is mainly dependent on the nature of the non-metallic portion of the 452 
compound”.13a 453 
It is well-known that the oxidation of benzoxazines constitutes one of the initial steps in their metabolic 454 
degradation.8,32 The electrochemical and computational studies presented here show that oxidation of 455 
6c and 6d requires the removal of one electron from their HOMO which is centred on the benzoxazine 456 
core in both cases, and that for 6d this process occurs at lower potentials than for its Re(I) analogue (6c) 457 
[EIIpa = 0.615 (for 6d) versus 0.702 (for 6c)] and therefore more accessible in the biological media. On 458 
this basis the Mn(I) complex is more prone to oxidize than its Re(I) analogue and this may produce 459 
radicals and even reactive oxygen and nitrogen species (ROS and RNS) that play an important role in 460 
cell survival, for instance as signalling molecules regulating the neutrophil function. 461 
462 
Conclusions 463 
The two first examples of an unprecedented type of organometallic 2-substituted 2,4-dihydro-1H-3,1-464 
benzoxazines with [M(η5-C5H4)(CO)3] arrays and M = Re (6c) or Mn (6d) at position-2 have been 465 
prepared and characterized in the solid state and also in solution. NMR and electrochemical studies of 466 
6c, 6d and their ferrocenyl (6a) or phenyl (6b) analogues (previously reported) have allowed us to 467 
establish the influence of the substituents [ferrocenyl (a), phenyl (b), cyrhetrenyl (c) or cymantrenyl (d)] 468 
on the ease with which benzoxazines 6a–6d undergo: (a) the ring opening process to give 5a–5d and (b) 469 
oxidation. 470 
Theoretical studies based on DFT and TD-DFT methodologies for 5a–5d and 6a–6d have allowed us to 471 
elucidate the effect of the substituents on the relative stability {in a vacuum and in CH2Cl2 solution} 472 
and the electronic distribution of the closed 6a–6d and open forms 5a–5d. These calculations have been 473 
extremely useful to understand the different proclivities of the closed forms (6a–6d) to undergo the 474 
opening of the sixmembered 1,3 N,O heterocycle to give their imine partners (5a–5d). 475 
The results obtained from the biological studies demonstrate that the replacement of the Re(I) of 6c by 476 
Mn(I) to give 6d induces significant changes in their biological activities. The Re(I) complex 6c, with no 477 
significant antichagasic activity, showed a moderate inhibitory growth effect on the MCF7 cancer cell 478 
line, while its Mn(I) analogue (6c) (inactive in the cancer cells) exhibited moderate anti-Trypanosoma 479 
cruzi activity. Despite the fact that the inhibitory growth effects of 6c in the MCF7 cancer cell line or of 480 
6d in the Dm28c strain are far from those of cisplatin or nifurtimox respectively, their remarkable 481 
stability (in the solid state and in DMSO solutions) at 298 K and their low toxicity in normal and non-482 
tumoral BJ cell lines make them extremely attractive for further studies aimed to check their effect on 483 
other cancer cell lines and/or other parasites (i.e. as antimalarials). Besides, the results summarized here 484 
open up a bunch of new possibilities based on: (a) substitution of the CO ligands by phosphines, (b) 485 
their utility as ligands in front of transition metal ions or (c) the extension of the methods reported here 486 
to half-sandwich complexes with other transition metals (i.e. Cr, Tc), with different properties, activities 487 
and potential utilities.  488 
In addition, since benzoxazine derivatives are becoming more and more popular as precursors for the 489 
preparation of resins or polymers, the new compounds presented here may also be attractive from this 490 
point of view. The presence of the “[M(η5-C5H4)(CO)3]” cores [M = Re(I) (in 6c) or Mn(I) (in 6d)] 491 
may be useful to achieve new types of organometallic resins and/or polymers. 492 
493 
Experimental 494 
Materials and methods 495 
The aldehydes [M(η5-C5H4-CHO)(CO)3] with M = Re or Mn and compounds 6a and 6b were prepared 496 
as described previously. 6,23,24 The aminoalcohols H2N-C6H4-2-(CH2)nOH (n = 1 or 0) were 497 
purchased from Sigma-Aldrich and used as received. The preparation of the new compounds requires 498 
the use of benzene as a solvent, which should be used with CAUTION! This solvent as well as ethyl 499 
acetate (HPLC-grade) were obtained from commercial sources and used as received, and the remaining 500 
solvents (n-hexane and CH2Cl2) used during the synthesis and purification of the compounds were 501 
purified using the standard methods.43 The deuterated solvents used for the NMR studies were 502 
purchased from Sigma-Aldrich (benzene-d6 (99.9%) and CD2Cl2 (99.9%)) or from Acros-Organics 503 
[acetonitrile-d3 (99.95%), CDCl3 (99.8%) or DMSO-d6 (99.5%)]. All manipulations were performed 504 
under an N2 atmosphere using Schlenk techniques. 505 
High resolution mass spectra (HRMS) were recorded at the Servei d’ Espectrometría de Masses (Univ. 506 
Barcelona) using a LC/MSD-TOF Agilent Technologies instrument and electron impact (EI) mass 507 
spectra were obtained with a Shimadzu CC-MS spectrometer (70 eV) at the Laboratorio de Servicios 508 
Analíticos (Pontificia Universidad Católica de Valparaiso). C, H and N analyses were performed with an 509 
Eager 1108 microanalyzer. Infrared (IR) spectra of the new compounds were registered with a Nicolet 510 
400 FTIR instrument using KBr pellets. Proton and 13C{1H}-NMR spectra of the new products in 511 
acetonitrile- d3 were recorded at 298 K with a Mercury 400 MHz instrument. These NMR data are 512 
presented in the characterization section of the corresponding compound and the spectra are shown in 513 
Fig. S7–S10.† The assignment of the signals detected was achieved with the aid of two-dimensional 514 
NMR experiments: [1H–1H]-Nuclear Overhauser Effect Spectroscopy (Fig. S11 and S12†) (NOESY), 515 
[1H–13C] Heteronuclear Single Quantum Coherence Spectroscopy (HSQC) (Fig. S13 and S14†) and 516 
Heteronuclear Multiple-Bond Correlation Spectroscopy (HMBC) (Fig. S15 and S16†). 517 
Additional 1H-NMR studies of the new compounds in CD2Cl2 (Fig. S17 and S18†), and of their 518 
ferrocenyl and phenyl analogues (Fig. S19 and S20†) and complementary studies [in benzene-d6 (Fig. 519 
S21 and S22†) and DMSO-d6 (Fig. S25 and S26†)] together with 13C{1H}-NMR studies of 6c and 6d 520 
in benzene and CD2Cl2 (Fig. S23 and S24†) were also carried out at 298 K in order to elucidate the 521 
effect induced by these solvents on the tautomeric equilibria and to fulfill the characterization of 6c and 522 
6d in solution. NMR spectra of imines 7c and 7d in CDCl3 at 298 K (Fig. S27 and S28,† respectively) 523 
and the studies of their stability in DMSO-d6 and after several periods of storage were carried out at 298 524 
K (Fig. S29 and S30,† respectively). In all cases, chemical shifts (δ) are given in ppm and the coupling 525 
constants ( J) in Hz. The assignment of the resonances observed refers to the labelling patterns presented 526 
in Fig. S6† and the abbreviations for the multiplicities of the signals are as follows: s (singlet), d 527 
(doublet), t (triplet), m (multiplet), dd (doublet of doublets) and br (broad). Finally, the ultraviolet-528 
visible (UV-vis) spectra of 1 × 10−5 M solutions of compounds 6a–6d in CH2Cl2 were recorded with a 529 
CARY 100 scan Varian UV spectrometer at 298 K (Fig. S31†).  530 
 531 
Preparation of the compounds 532 
2-Cyrhetrenyl-2,4-dihydro-1H-3,1-benzoxazine (6c). Cyrhetrenylcarboxaldehyde (100 mg, 0.275 mmol) 533 
and the stoichiometric amount of 2-aminobenzylalcohol (33.9 mg, 0.275 mmol) were suspended in 20 534 
mL of benzene. The flask was connected to a condenser equipped with a Dean–Stark apparatus, to 535 
remove the benzene–water azeotrope formed and the reaction mixture was stirred under reflux for 12 h. 536 
After this period, the hot solution was concentrated to dryness on a rotary evaporator. Further treatment 537 
of the residue formed with n-hexane gave the corresponding compound as pale greenish microcrystals. 538 
[Yield: 116 mg, 0.25 mmol, 90%]. Characterization data: M.p. = 148° C; mass spectrum (Fig. S1†): 539 
HRMS (m/z): 470.0394 and calc. for {[M] + H}+(C16H12NO4Re): 470.0402 and EI-MS: (based on 540 
187Re): m/z = 469, [M]+; 441 {[M] − CO}+; 413 {[M] − 2CO}+ and 385 {[M] − 3CO}+. IR (selected 541 
data) (in cm−1): 3324 [ν(CvN)], 2019 [ν(CO)] and 1905 [ν(CO)]. 1H-NMR data [in acetonitrile-d3, 542 
(400 MHz) at 298 K (Fig. S7†)]: δ1H, 7.07(t, 1H, J = 8.1, H4), 6.94 (d, J = 7.5, H3), 6.78(t, 1H, J = 7.5, 543 
H5), 6.71(d, 1H, J = 7.6, H6), 5.72–5.68[2m(partially overlapped), 2H, H2 and H5], 5.36(d, 1H, J = 4.0, 544 
H8), 5.49(m, 1H, H4), 5.45(m, 1H, H3), 4.97(d, 1H, J = 14.1, H7), 4.78(d, 1H, J = 14.1, H7) and 545 
4.74[br. 1H, –NH– ( partially overlapped by the resonance due to one of the protons H7]; 13C{1H}-546 
NMR data [in acetonitrile-d3 (125 MHz), at 298 K (Fig. S9†)]: δ13C = 195.3(CO), 142.5(C2), 547 
127.5(C4), 124.9(C3), 122.6(C1), 119.4(C5), 116.7(C6), 109.4(C1), 84.9(C4), 84.4(C2), 83.5(C5), 548 
84.1(C3), 79.2(C8), 66.7(C7). Anal. (%) calcd for C16H12NO4Re: C, 41.02; H, 2.58 and N, 2.99. 549 
Found: C, 41.0; H, 2.6 and N, 3.0 550 
2-Cymantrenyl-2,4-dihydro-1H-3,1-benzoxazine (6d). 2-Aminobenzylalcohol (53.1 mg, 0.431 mmol) 551 
was added to a solution of cymantrenylcarboxaldehyde (120 mg, 0.517 mmol) in 20 mL of benzene. The 552 
flask was connected to a condenser equipped with a Dean–Stark apparatus to remove the benzene–water 553 
azeotrope formed, and the mixture was refluxed for 24 h. After this period, the hot solution was 554 
concentrated to dryness on a rotary evaporator. The residue was dissolved in a minimum amount of 555 
ethyl acetate. The work up of SiO2 column chromatography on silica gel (eluent n-hexane : ethyl 556 
acetate, 90 : 10) produced the release of a band that was collected and concentrated to dryness giving a 557 
gummy residue. 1H-NMR spectra of this residue revealed the coexistence of compound 6d and traces of 558 
the aldehyde. This minor component was removed by subsequent washings of the residue with n-559 
hexane. Finally, the brownish dust powder isolated was dried under vacuum. [Yield: 103.2 mg, 560 
0.30mmol, 71%]. Characterization data: M.p. = 120° C; mass spectrum (Fig. S4†): HRMS: m/z = 561 
338.0220 and calc. for: {[M] + H}+(C16H13MnNO4): 338.0225 and EI-MS: (based on 55Mn): m/z = 562 
337 [M]+; 309 {[M] − CO}+; 281 {[M] − 2CO}+; 253 {[M] − 3CO}+. IR selected data (KBr; cm−1): 563 
3322 [ν(N–H)], 2019 [ν(CO)] and 1932 [ν(CO)]. 1H-NMR data [in acetonitrile-d3, (400 MHz) at 298 K 564 
(Fig. S8†)]: δ1H = 7.10(t, 1H, J = 8.1, H4), 6.78(d, 1H, J = 7.5, H3), 6.75(t, 1H, J = 8.0, H5), 6.72(d, 1H, 565 
J = 8.0, H6), 5.32(d, 1H, J = 4.6, H8), 5.09–5.07[2m(partially overlapped) 2H, H2 and H5], 4.97(d, 1H, 566 
J = 14.8, one of the protons H7), 4.90–4.70(br. m, 3H, –NH–, H3 and H4), 4.79(d, 1H, J = 14.8, the 567 
other H7); 13C{1H}-NMR data [in acetonitrile-d3 (125 MHz), at 298 K, (Fig. S10†)]: δ13C = 568 
142.6(C2), 128.2(C4), 125.3(C3), 122.5(C1), 120.2(C5), 117.5(C6′), 105.2(C1), 80.5(C7), 67.8(C8), 569 
84.9 and 84.4(C2 and C5), 84.1 and 83.3(C3 and C4).44 Anal. (%) calcd for C16H12MnNO4: C, 56.99; 570 
H, 3.59 and N, 4.15. Found: C, 56.9; H, 3.6 and N, 4.1. 571 
Compounds [M{(η5-C5H4)-CHvN-(C6H4-2-OH)}(CO)3] (7) {M = Re (7c) or Mn (7d)}. These new 572 
cyrhetrenyl and cymantrenyl imino complexes were prepared as described above for 6c. For compound 573 
7c: 2-aminophenol (22.5 mg, 0.21 mmol) and the aldehyde [Re(η5-C5H4-CHO)(CO)3] (75 mg, 0.21 574 
mmol) were dissolved in benzene (20 mL). Then the reaction flask was connected to a Dean–Stark 575 
apparatus and refluxed for 12. Afterwards, the solvent was removed under vacuum and the solid formed 576 
was washed with small portions of n-hexane and then dried under vacuum. Imine 7d was prepared 577 
following the same procedure but using cymantrenylcarboxaldehyde (75 mg, 0.32 mmol) and 35.3 mg 578 
(0.32 mmol) of 2-aminophenol. Compounds 7c and 7d were finally isolated as yellow microcrystals and 579 
as a nearly black solid, respectively. [Yields: 80.1 mg (0.18 mmol, 86%) for 7c and 52.2 mg (0.16 580 
mmol, 50%) for 7d]. Characterization data for 7c: M.p. = 107° C; mass spectrum: HRMS (m/z): 581 
456.0240 calc. for {[M] + H}+ (C15H11NO4Re): 456.0241 and EI-MS (based on 187Re): m/z = 455, 582 
[M]+; 427 {[M] − CO}+; 399 {[M] − 2CO}+ and 371 {[M] − 3CO}+. IR (selected data) (in cm−1): 583 
2015 [ν(CO)], 1941 [ν(CO)] and 1633 [ν(CvN)]. 1H-NMR data [in CDCl3, (400 MHz) at 298 K]: δ1H = 584 
8.32(s, 1H, –CHvN–), 7.19[m, 2H, H4 and –OH (overlapped signals)], 6.99(dd, 1H, J = 8.1 and 1.3, 585 
H6), 6.88(td, 2H, J = 7.5 and 1.2, H5 and H3), 6.02(t, 2H, J = 2.3, H2 and H5), 5.46(t, 2H, J = 2.3, H3 586 
and H4). 13C{1H}-NMR data [in CDCl3, (101 MHz), at 298 K]: δ13C = 192.7(CO), 152.0(–CHvN–), 587 
149.5 (C2), 134.9(C1), 129.5(C4), 120.4(C3), 116.1(C5), 115.4(C6), 98.7 (C1), 86.5(C2 and C5) and 588 
85.0(C3 and C4). Characterization data for 7d: M.p. = 90° C; mass spectrum: HRMS (m/z): 324.0063, 589 
calc. for {[M] + H}+ C15H11NO4Mn: 324.0063 and EI-MS (based on 55Mn): m/z = 323, [M]+; 295 590 
{[M] − CO}+; 267 {[M] − 2CO}+ and 239 {[M] − 3CO}+. IR (selected data) (in cm−1): 2022 [ν(CO)], 591 
1930 [ν(CO)] and 1623 [ν(CvN)]. 1H-NMR data [in CDCl3, (400 MHz) at 298 K]: δ1H, 8.29(s, 1H, –592 
CHvN–), 7.18[m, 2H, H4 and –OH (overlapped signals)], 6.99 (dd, 1H, J = 8.3 and 0.9, H6), 6.88(m, 593 




X-ray crystals of compounds 6a, 6c and 6d were obtained by slow evaporation (at 298 K) of a CH2Cl2 598 
solution of the corresponding product layered with n-hexane. A crystal of 6a, 6c or 6d (sizes in Table 599 
S1†) was used for the X-ray analysis. X-ray intensity data were measured on a D8 Quest system (for 6a) 600 
or on a D8 Venture system (for 6c and 6d) equipped with a multilayer monochromator and a Mo-601 
microfocus (λ = 0.71073 Å).  602 
For 6a, 6c and 6d the frames were integrated with a Bruker SAINT software package using a narrow 603 
frame algorithm. The integration of data using a monoclinic (for 6a), an orthorhombic (for 6c) or a 604 
monoclinic (for 6d) unit cell yielded for 6a: a total of 16 003 reflections to a maximum θ angle of 605 
26.416° (0.72 Å resolution), of which 2941 were independent (average redundancy 3.338, completeness 606 
= 99.6%, Rint = 2.58%, Rsig = 2.36%). For 6c, which was a twin crystal, a total of 25 066 reflections to 607 
a maximum θ angle of 29.554° (0.72 Å resolution) of which 7511 were independent (average 608 
redundancy 3.337, completeness = 99.7%, Rint = 4.02%, Rsig = 4.60%); and for 6d: 35 346 reflections 609 
to a maximum θ angle of 30.174° (0.71 Å resolution) of which 4058 were independent (average 610 
redundancy 8.710, completeness = 99.4%, Rint = 9.07%, Rsig = 5.17%). The number of reflections 611 
greater than 2σ(F2) was: 2831 (for 6a), 6741 (for 6c) and 3228 (for 6d). 612 
The final cell parameters for 6a, 6c and 6d presented in Table 1 are based upon the refinement of XYZ 613 
centroids of reflections above 20 σ(I). Data were corrected for absorption effects using the multi-scan 614 
method (SADABS). The calculated minimum and maximum transmission coefficients based on crystal 615 
sizes are given in Table 1. 616 
The structures were solved and refined using the Bruker SHELXTL software package using the space 617 
group P21 (for 6a), Pna21 (for 6c) and C2/c (for 6d) (Z = 8 in both cases) for the formula units 618 
C18H17NOFe (in 6a) and C16H12NO4M {M = Re (in 6c) or Mn (in 6d)}. The final anisotropic full-619 
matrix leastsquares refinements on F2 with 165 variables (for 6a), 386 for 6c and 199 for 6d converged 620 
at R1 = 2.29%, (observed data) and wR2 = 5.45% (for all data) for 6a; at R1 = 3.59%, (observed data) 621 
and wR2 = 8.22% (all data) for 6c and at R1 = 4.58%, (observed data) and wR2 = 12.27% (all data) for 622 
6d. The goodness of fit and further details concerning the resolution and refinement of the crystal 623 
structures of 6a, 6c and 6d are presented in Table S1.† CCDC 1858655 (for 6a), 1858656 (for 6c) and 624 




Electrochemical studies 629 
Cyclic voltammetric (CV) studies were carried out at room temperature using a Metrohm Autolab 630 
potentiostat and a three-electrode cell. Each compound was dissolved in acetonitrile containing 0.1 mol 631 
L−1 of tetrabutylammonium hexafluorophosphate (Bu4N)[PF6] as a supporting electrolyte to give 10−3 632 
mol L−1 final concentration. A 2 mm platinum working electrode and a platinum coil counter electrode 633 
were used. The reference electrode contained a silver wire with 10 mM silver nitrate in (Bu4N)[PF6] 634 
electrolyte solution. 635 
The working electrode was polished with 0.3 and 0.05 μm alumina slurries, rinsed with distilled water 636 
(18 MΩ cm) and acetone, and dried prior to use. All electrolyte solutions were thoroughly pre-purged 637 
using purified nitrogen gas before use. The measurements were carried out at 250 mV s−1 scan rate. The 638 
ferrocene/ferricinium (Fc/Fc+) couple served as the internal reference and appeared at +89 mV (vs. 639 
Ag/Ag+) for each experiment. 640 
 641 
Computational studies 642 
DFT calculations were carried out using Gaussian 03 software40 with the B3LYP functional.37 The 643 
basis set was chosen as follows: LANL2DZ (for Fe, Re and Mn) and 6-31G* (including polarization 644 
functions for non-hydrogen atoms) for O, N, C and H.39 Geometry optimizations were performed 645 
without symmetry restrictions. Solvent effects have been included using the CPCM method.45 646 
 647 
Biological studies 648 
Cell culture. Colon adenocarcinoma (HCT116) cells (from the American Type Culture Collection) and 649 
breast cancer (MDA-MB231 and MCF7) cells (from European Collection of Cell Cultures, ECACC) 650 
were used for all the experiments. The cells were grown as a monolayer culture in DMEM-high glucose 651 
(Sigma, D5796) in the presence of 10% heat-inactivated fetal calf serum and 0.1% 652 
streptomycin/penicillin under standard culture conditions. The human skin fibroblast cell line BJ was 653 
cultured in MEM (Sigma, M2279) in the presence of 10% FBS, 4 mM glutamine and 0.5% 654 
streptomycin/penicillin. All the cells were incubated under standard conditions (humidified air with 5% 655 
CO2 at 37 °C). The cells were passaged at 90% confluence by washing once with cation-free HBSS 656 
followed by a 3 min incubation with trypsin ([0.5 μg mL−1]/EDTA [0.2 μg mL−1]) (Gibco-BRL, 657 
15400054) solution in HBSS at 37 °C, and transferred to its medium. Prior to seeding at a defined cell 658 
concentration, the cells were recovered from the medium by centrifugation and counted. 659 
Cell viability assays. For these studies, compounds 6c and 6d were dissolved in 100% DMSO at 50 mM 660 
as stock solution; then, consecutive dilutions have been done in DMSO (1 : 1) (in this way DMSO 661 
concentration in cell media was always the same); followed by 1 : 500 dilutions of the solutions of 662 
compounds on cell media. Cisplatin was dissolved in water Milli-Q® and used immediately after its 663 
preparation. The assay was carried out as described by Givens et al.46 In brief, MDA-MB231 and 664 
MCF7 cells were plated at 5000 cells per well or 10 000 cells per well respectively, in 100 μL media in 665 
tissue culture 96 well plates (Cultek). BJ cells were plated at 2500 cells per well. After 24 h, the medium 666 
was replaced by 100 μL per well of serial dilution of drugs. Each point concentration was run in 667 
triplicate. Reagent blanks, containing media plus colorimetric reagent without the cells, were run on 668 
each plate. Blank values were subtracted from test values and were routinely 5–10% of uninhibited 669 
control values. Plates were incubated for 72 h. Hexosaminidase activity was measured according to the 670 
following protocol: the media containing the cells were removed and the cells were washed once with 671 
phosphate buffer saline (PBS) and 60 μL of substrate solution (7.5 mM p-nitrophenol-N-acetyl-β-D-672 
glucosamide [Sigma N9376], 0.1 M sodium citrate, pH = 5.0, 0.25% Triton X-100) was added to each 673 
well and incubated at 37 °C for 1–2 h; after this incubation time, a bright yellow colour appeared; then, 674 
plates could be developed by adding 90 μL of developer solution (glycine 50 mM, pH = 10.4; EDTA 5 675 
mM), and absorbance was recorded at 410 nm. 676 
 677 
In vitro anti-trypanosomal activity 678 
Parasites. Trypanosoma cruzi, epimastigotes (Dm28c strain), from our own collection (Clinical and 679 
Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Faculty of Medicine, 680 
University of Chile), were grown at 28 °C in LIT medium, with 4 μM hemin, supplemented with 681 
inactive 10% v/v FBS, 100 U mL−1 penicillin, and 100 mg mL−1 streptomycin at 28 °C. The parasites 682 
were harvested and collected for viability. 683 
Anti-proliferative assays. All compounds were dissolved in DMSO (final concentration was less than 684 
0.5% v/v) at a concentration range (1–100 μM), added to a suspension of epimastigotes (3 × 106 685 
parasites per mL) and incubated for 24 h at 37 °C. Nifurtimox was added as a positive control. Later, 686 
MTT47 was added at a final concentration of 0.5 mg mL−1 with phenazine methosulfate (0.22 mg 687 
mL−1) and incubated at 37 °C for 4 h. The parasites were solubilized in 10% sodium dodecyl sulfate–688 
0.01 M HCl and incubated overnight beforedetermining the number of viable parasites. The optical 689 
density (OD) was determined using a microplate reader (Asys Expert Plus©, Austria) at 570 nm. Under 690 
these conditions, the OD is directly proportional to the viable cell number in each well. All experiments 691 
were performed in triplicate and data are shown as the means and their standard deviations from 692 
triplicate cultures. The IC50 values were obtained using non-linear dose–response curve fitting analysis 693 
(log of concentration vs percentage of viable cells) via Graph Pad Prism 5 software.48 694 
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 922 
Scheme 1 Five- and six-endo trig processes (E = S or O). 923 
 924 
Fig. 1 Selection of cyrhetrene and cymantrene derivatives with relevant antiparasitic or antitumoral 925 
activity described. (For comparison purposes, compound V, closely related to IV, has also been 926 
included.) 927 
 928 
Fig. 2 Examples of ferrocene derivatives showing ring-chain tautomerism reported so far.5–7 For 929 
comparison purposes the 6-endo trig process of the aldimine 5b and its closed form (6b) is also included. 930 
 931 
Scheme 2 Synthesis of the new compounds and six-endo trig process under study. (i) For M = Re: 932 
equimolar amount of the reagents in refluxing benzene with a Dean–Stark apparatus for 12 h and for M 933 
= Mn: treatment of the aminoalcohol with an excess (20%) of the aldehyde in benzene under reflux with 934 
a Dean–Stark apparatus for 24 h, followed by the work-up of SiO2 column chromatography using a 935 
mixture of ethyl acetate : hexane (10 : 90) as the eluent, followed by concentration and washings with n-936 
hexane. 937 
 938 
Fig. 3 ORTEP diagram for compound 6a. Thermal ellipsoids are shown at 50% probability level. 939 
 940 
Fig. 4 ORTEP diagrams of molecules (A and B) found in the crystals of compound 6c. Thermal 941 
ellipsoids are shown at 50% probability level. 942 
 943 
Fig. 5 ORTEP diagram for compound 6d. Thermal ellipsoids are shown at 50% probability level. 944 
 945 
Fig. 6 Cyclic voltammograms of 2-[ferrocenyl, phenyl, cyrhetrenyl or cymantrenyl]-2,4-dihydro-1H-946 
3,1-benzoxazines (6a–6d, respectively), in the range of potentials −1.2 V ≤ E ≤ 1.6 V, together with the 947 
labelling system used to identify the observed peaks. For the ferrocenyl derivative (6a) the cyclic 948 
voltammogram in the range −1.2 V ≤ E ≤ 0.6 V is shown in grey color as an inset of the CV. The 949 
vertical dotted lines are presented for comparison purposes. 950 
 951 
Fig. 7 Frontier orbitals [HOMO−1, HOMO, LUMO and LUMO+1] for the 2-ferrocenyl- (6a), phenyl- 952 
(6b), cyrhetrenyl- (6c) or cymantrenyl- (6d) 2,4-dihydro-1H-3,1-benzoxazines under study. 953 
 954 
Fig. 8 Inhibition of cell growth proliferation in the colon (HCT-116) and breast (MDA-MB231 and 955 
MCF7) cancer cell lines after 72 h of exposure to 2-cyrhetrenyl- (6c) or cymantrenyl- (6d) 2,4-dihydro-956 
1H-3.1-benzoxazines and cisplatin. 957 
Fig. 9 Inhibition of cell growth proliferation in the normal and nontumoral human skin fibroblast BJ cell 958 
line of compounds 6c and 6d and cisplatin under identical experimental conditions. 959 
 960 
Fig. 10 Effect of 2-cyrhetrenyl- (6c) or cymantrenyl- (6d) -2,4-dihydro-1H-3.1-benzoxazines and 961 
nifurtimox on the Trypanosoma cruzi epimastigotes (Dm28c strain). 962 
963 

































































Table 1 Selected bond lengths (in Å), bond angles (in °) of the 2-ferrocenyl-2,4-dihydro-1H-3,1-1029 
benzoxazine (6a) and its analogues with the cyrhetrenyl (in 6c) or the cymantrenyl (in 6d) unit on 1030 







Table 2 Summary of the electrochemical data [anodic (EIpa) potentials and cathodic potential (EI’ pc) 1038 
(in V)]. Data were obtained at a scan rate υ =250 mV s−1 and referenced to the ferrocene/ferricinium 1039 





Table 3 Anticancer and antichagasic activities of the new 2-cyrhetrenyl-(6c) or cymantrenyl- (6d) 2,4-1045 
dihydro-1H-3,1-benzoxazines (6c and 6d, respectively) (IC50 values in μM)a against: the colon cell line 1046 
HCT-116, the two breast cancer cell lines [MDA-MB231 and MCF7 ] and Trypanosoma cruzi 1047 
epimastigotes (Dm28c strain). For comparison purposes, data obtained for cisplatin in the cancer cell 1048 
lines or for nifurtimox in Trypanosoma cruzi epimastigotes (Dm28c strain) under identical experimental 1049 
conditions are also included 1050 
 1051 
 1052 
